A61P 11 - Drugs for disorders of the respiratory system

Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
11/2001
11/15/2001	CA2408647A1 Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
11/15/2001	CA2408549A1 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/15/2001	CA2408547A1 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/15/2001	CA2408297A1 Cancer diagnosis and assays for screening anti-cancer agents
11/15/2001	CA2408234A1 Peptide deformylase inhibitors
11/15/2001	CA2408213A1 Protein complexes and assays for screening anti-cancer agents
11/15/2001	CA2408002A1 Enzymatic assays for screening anti-cancer agents
11/15/2001	CA2407865A1 Novel eosinophil cationic proteins used in the treatment of asthmatic and allergic disorders
11/15/2001	CA2407850A1 Cytoskeleton-associated proteins
11/15/2001	CA2407830A1 Amino acid derivatives and their use as medicines
11/15/2001	CA2406512A1 Pharmaceutical compounds for treating copd
11/14/2001	EP1154019A2 G-protein coupled receptor (HFGAN72X)
11/14/2001	EP1153129A1 Method of treating restenosis by antisense targeting of c-myc
11/14/2001	EP1153121A2 Secreted proteins and polynucleotides encoding them
11/14/2001	EP1153038A1 Therapeutics and diagnostics based on a il-1b mutation
11/14/2001	EP1153017A1 Bicyclic compounds and their use as integrin receptor ligands
11/14/2001	EP1152770A1 Small peptides and methods for treatment of asthma and inflammation
11/14/2001	EP1152759A2 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
11/14/2001	EP1152753A1 Combinations of formoterol and fluticasone propionate for asthma
11/14/2001	EP1003537B1 Composition comprising propolis and at least an essential oil
11/14/2001	EP0777482B1 Combined preparation for the therapy of immune diseases
11/14/2001	EP0763037B1 [a]-ANNELATED PYRROLE DERIVATIVES AND PHARMACEUTICAL USE THEREOF
11/14/2001	CN1322212A Neuropeptide Y agaonists
11/14/2001	CN1322196A Naphthalenecaarboxamides as tachykinin receptor antagonists
11/14/2001	CN1322134A Naphthalenecarboxamides as tachykinin receptor antagonists
11/14/2001	CN1321745A Macrophage inflammatory protein -3, -4 and -1 gamma
11/14/2001	CN1321639A Substd. heterocyclic compounds, preparing process thereof and pharmaceutical composition contg them
11/14/2001	CN1321634A Substd heterocyclic compounds preparing method thereof and pharmaceutical composition contg. them
11/14/2001	CN1321512A Ebikang medicine for treating nasal disorders and its preparation method
11/13/2001	US6316648 Purified 5,6,15-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid; anticarcinogenic and antiproliferative agents
11/13/2001	US6316601 Antibodies specific for β6 integrins
11/13/2001	US6316478 IL-8 receptor antagonists
11/13/2001	US6316475 Treatment of cancer, asthma, heart diseases, seizures, inflammation
11/13/2001	US6316472 Heterosubstituted pyridine derivatives as PDE 4 inhibitors
11/13/2001	US6316466 Pyrazole derivatives P-38 MAP kinase inhibitors
11/13/2001	US6316464 P38 MAP kinase inhibitors
11/13/2001	US6316457 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
11/13/2001	US6316433 Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
11/13/2001	US6316403 Deactivation of factor ix for coagulation inhibition and antiischemic agents
11/13/2001	US6316227 Dna sequence encoding a composite heavy chain of a recombinant antibody molecule that specifically binds human interleukin-5 antigen
11/13/2001	US6315995 Adding to blood inactive recombinant mutein comprising proteolytically inactive mutein of factor ix or ixa to inhibit clot formation, does not interfere with hemostasis when the blood is administered to a patient
11/13/2001	US6315983 Process for the production of powdered pulmonary surfactant preparations
11/13/2001	US6314956 Treating lung defects associated hypoxemia or smooth muscle constriction; administer ethyl nitrite to human and monitor
11/08/2001	WO2001083775A2 Proteases
11/08/2001	WO2001083772A1 Splice variant of camp phosphodiesterase type 7 (pde7a3)
11/08/2001	WO2001083744A2 Natrium-calcium exchanger protein
11/08/2001	WO2001083554A2 Anti-inflammatory compounds and uses thereof
11/08/2001	WO2001083547A2 Anti-inflammatory compounds and uses thereof
11/08/2001	WO2001083543A1 Human wingless-like gene
11/08/2001	WO2001083512A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001	WO2001083510A1 29 human secreted proteins
11/08/2001	WO2001083489A1 THIENO[2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
11/08/2001	WO2001083484A1 Pyrano, piperidino, and thiopyrano compounds and methods of use
11/08/2001	WO2001083475A1 Novel heterocyclic compounds with anti-inflammatory activity
11/08/2001	WO2001083462A1 Novel, slow-acting betamimetics, a method for their production and their use as medicaments
11/08/2001	WO2001083461A1 Thiazole and oxazole derivatives
11/08/2001	WO2001083454A1 Benzosuberonylpiperidine compounds as analgesics
11/08/2001	WO2001083445A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
11/08/2001	WO2001083438A2 New gamma selective retinoids
11/08/2001	WO2001083431A1 Mmp-12 inhibitors
11/08/2001	WO2001082966A1 Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
11/08/2001	WO2001082965A1 Combination therapy of respiratory diseases using antibodies
11/08/2001	WO2001082958A2 Methods of producing membrane vesicles
11/08/2001	WO2001082953A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001	WO2001082952A2 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
11/08/2001	WO2001082895A2 Guaifenesin sustained release formulation and tablets
11/08/2001	WO2001082868A2 A medicinal aerosol formulation
11/08/2001	WO2001060349A3 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof.
11/08/2001	WO2001041760A3 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/08/2001	WO2001039777A8 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
11/08/2001	WO2001037780A8 Urotensin-ii analogs
11/08/2001	WO2001036630A3 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
11/08/2001	WO2001034180A3 Interferon gamma for the treatment of asthma
11/08/2001	WO2001032614A3 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof
11/08/2001	WO2001028582A3 Therapeutic applications of flint polypeptides
11/08/2001	WO2001008707A3 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
11/08/2001	US20010039289 Antagonists; especially sodium salts
11/08/2001	US20010039282 Desloratadine as non-sedating antihistamine, decongestant
11/08/2001	US20010039274 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease
11/08/2001	US20010039271 For treatment of male erectile dysfunction, female sexual dysfunction
11/08/2001	US20010039038 Novel glucosaminidase
11/08/2001	US20010038843 Immunogenic polypeptide comprising a self Immunoglobin E (IgE) portion and a non-self IgE portion, to induce an anti-self IgE response in a mammal; treating diseases such as allergies
11/08/2001	US20010037808 Methods and devices for use in performing pulmonary procedures
11/08/2001	DE10019755A1 New cyclic carboxylic acids are integrin antagonists, useful for treating inflammatory diseases, autoimmune and immune disorders, e.g. atherosclerosis, asthma and diabetes
11/08/2001	CA2418748A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001	CA2414296A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2414290A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2409689A1 Combination therapy of respiratory diseases using antibodies
11/08/2001	CA2407959A1 Human wingless-like gene
11/08/2001	CA2407887A1 Natrium-calcium exchanger protein
11/08/2001	CA2407797A1 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001	CA2407785A1 Use of .alpha.-msh and epo for preventing or treating ischemic conditions
11/08/2001	CA2407746A1 Proteases
11/08/2001	CA2407604A1 Splice variant of camp phosphodiesterase type 7 (pde7a3)
11/08/2001	CA2407418A1 Novel heterocyclic compounds with anti-inflammatory activity
11/08/2001	CA2407292A1 Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
11/08/2001	CA2407225A1 Methods of producing membrane vesicles
11/08/2001	CA2407189A1 New gamma selective retinoids
11/08/2001	CA2405745A1 New betamimetics having a long-lasting activity, processes for preparingthem and their use as medicaments
11/08/2001	CA2403901A1 29 human secreted proteins

1 ... 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 ... 878